Urogen Pharma (NASDAQ:URGN) Rating Increased to Buy at ValuEngine

Urogen Pharma (NASDAQ:URGN) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, ValuEngine reports.

Several other brokerages have also recently commented on URGN. JPMorgan Chase & Co. started coverage on shares of Urogen Pharma in a report on Thursday, May 30th. They set a “neutral” rating and a $41.00 target price on the stock. HC Wainwright set a $75.00 target price on shares of Urogen Pharma and gave the stock a “buy” rating in a report on Tuesday, May 28th. Zacks Investment Research cut shares of Urogen Pharma from a “buy” rating to a “hold” rating in a report on Tuesday. Goldman Sachs Group started coverage on shares of Urogen Pharma in a report on Wednesday, May 29th. They set a “neutral” rating and a $50.00 target price on the stock. Finally, Cowen reaffirmed a “buy” rating on shares of Urogen Pharma in a report on Monday, May 6th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $59.00.

Shares of URGN traded down $0.62 during mid-day trading on Thursday, hitting $34.33. 240,357 shares of the company’s stock were exchanged, compared to its average volume of 119,803. Urogen Pharma has a 52 week low of $30.48 and a 52 week high of $55.49. The stock has a 50-day moving average of $33.72. The stock has a market capitalization of $468.92 million, a price-to-earnings ratio of -7.15 and a beta of 1.22.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Thursday, May 9th. The company reported ($1.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.12) by $0.01. As a group, sell-side analysts forecast that Urogen Pharma will post -5.37 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of URGN. Public Employees Retirement Association of Colorado acquired a new stake in shares of Urogen Pharma during the 1st quarter worth approximately $41,000. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Urogen Pharma by 100.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,000 shares of the company’s stock worth $74,000 after acquiring an additional 1,000 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Urogen Pharma by 112.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,421 shares of the company’s stock worth $89,000 after acquiring an additional 1,282 shares in the last quarter. Strs Ohio acquired a new stake in shares of Urogen Pharma during the 2nd quarter worth approximately $179,000. Finally, Private Advisors LLC acquired a new stake in shares of Urogen Pharma during the 1st quarter worth approximately $329,000. Institutional investors and hedge funds own 97.78% of the company’s stock.

About Urogen Pharma

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Further Reading: Golden Cross

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.